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osting by EAbstract The aim of this study was to prepare and characterize solid dispersions of water insoluble
non-steroidal anti-inﬂammatory drug, indomethacin (IND), with polyethylene glycol 4000
(PEG4000) and Gelucire 50/13 (Gelu.) for enhancing the dissolution rate of the drug. The solid dis-
persions (SDs) were prepared by hot melting method at 1:1, 1:2 and 1:4 drug to polymer ratios.
Scanning electron microscopy (SEM), X-ray powder diffractometry (XRD) and differential scan-
ning calorimetry (DSC) were used to examine the physical state of the drug. Furthermore, the sol-
ubility and the dissolution rate of the drug in its different systems were explored. The data from the
XRD showed that the drug was still detectable in its solid state in all SDs of IND–Gelu. and dis-
appeared in case of higher ratio of IND–PEG4000. DSC thermograms showed the signiﬁcant
change in melting peak of the IND when prepared as SDs suggesting the change in crystallinity
of IND. The highest ratio of the polymer (1:4) enhanced the drug solubility about 4-folds or 3.5-
folds in case of SDs of IND–PEG or IND–Gelu., respectively. An increased dissolution rate of
IND at pH 1.2 and 7.4 was observed when the drug was dispersed in these carriers in form of phys-
ical mixtures (PMs) or SDs. IND released faster from the SDs than from the pure crystalline drug
or the PMs. The dissolution rate of IND from its PMs or SDs increased with an increasing amount
of polymer.
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lsevier1. Introduction
Indomethacin is a member of the non-steroidal anti-inﬂamma-
tory drugs (NSAIDs). It is used to reduce pain/swelling in-
volved in osteoarthritis, rheumatoid arthritis, bursitis,
tendinitis, gout, ankylosing spondylitis, and headaches (Sweet-
man, 2005). The drug is described as poorly soluble and highly
permeable (Class II) drug (Lobenberg and Amidon, 2000). Be-
cause water-insoluble drugs often show low absorption and
218 M. El-Badry et al.weak bioavailability, improvement in dissolution rate and/or
solubility are important for development of drug preparations
(Hirasawa et al., 2003). The successful formulation of poorly
water-soluble drugs is one of the major problems in pharma-
ceutical manufacturing. Indomethacin may show low and erra-
tic oral bioavailability due to poor dissolution of the drug in
the ﬂuids of the gastrointestinal tract. Additionally, this unde-
sirable physical property may increase the incidence of irritat-
ing side effects on the gastrointestinal tract because of a
prolonged contact time with the mucosa (Alsaidan et al.,
1998).
Over the years, a variety of solubilization techniques have
been studied to improve the dissolution rate of this widely used
antirheumatic agent, to obtain more rapid and complete
absorption such as; using adsorbants (Alsaidan et al., 1998;
Bogdanova et al., 2007), surfactant (Krasowska, 1980), hydro-
tropes and cosolvents (Etman and Nada, 1999), preparing
coprecipitate (Habib et al., 1993), liquisolid compacts
(Nokhodchi et al., 2005), fast releasing microparticles (Caval-
lari et al., 2007), interactive mixtures (Allahham and Stewart,
2007), solid dispersion (Valizadeh et al., 2004; Wang et al.,
2007), compressing with buffers (Preechagoon et al., 2000) or
complexation with cyclodextrins (Bandi et al., 2004; Jambhe-
kar et al., 2004).
Solid dispersion technique was selected as it was utilized in a
limited number of researches to increase the solubility of indo-
methacin. Solid dispersion (SD) is deﬁned as the dispersion of
one or more active ingredients in inert carriers at solid state
prepared by fusion, solvent, or solvent-fusion methods (Chiou
and Riegelman, 1971; Ford and Rubinstein, 1978). It has been
widely used to improve the dissolution rate, solubility and oral
absorption of poorly water-soluble drugs (El-Badry and Fathy,
2005, 2006; Douroumis et al., 2007; Thybo et al., 2007). In solid
dispersions, the particle size of the drugs was reduced, the
wettability and the dispersibility were enhanced; therefore,
drug dissolution was improved markedly (Abdul-Fattah and
Bhargava, 2002; Craig, 2002; Sethia and Squillante, 2004).
PEG and Gelucire are among the several carriers which
have been employed in preparing solid dispersions (Leuner
and Dressman, 2000) PEG polymers are widely used for their
low melting point, low toxicity, wide drug compatibility and
hydropholicity (Craig, 2002; Leuner and Dressman, 2000;
Lin and Cham, 1996; Liu and Desai, 2005; Urbanetz and Lip-
pold, 2005; Ahuja et al., 2007) Gelucire is a family of vehicles
derived from the mixtures of mono-, di- and triglycerides with
polyethylene glycol (PEG) esters of fatty acids. These are avail-
able with a range of properties depending on their hydro-
philic–lipophilic balance (HLB) and melting point range (33–
65 C) (Aı¨naoui and Vergnaud, 1998; Sutananta et al., 1994).
They have a wide variety of applications in pharmaceutical
formulations as the preparation of fast release and sustained
release formulations (Aı¨naoui et al., 1997; Dennis et al.,
1990; Cavallari et al., 2005).
The purpose of the current study is to characterize the so-
lid-state properties of the solid dispersion system of indometh-
acin in PEG4000 and Gelucire 50/13 prepared at different
ratios. The methods of characterization were achieved through
using different tools as scanning electron microscopy (SEM),
differential scanning calorimetry (DSC), powder X-ray diffrac-
tometry (XRD). Moreover, solubility and dissolution rate
study were performed to qualify the solid dispersion compar-
ing with the drug alone or as physical mixture (PM).2. Experimental
2.1. Materials
Indomethacin (IND) was kindly supplied by Egyptian Interna-
tional Pharmaceutical Co.; (EIPICO 10th of Ramadan city,
Egypt). PEG4000 was obtained from CLARIANT (Sulzbach,
Germany). Gelucire 50/13 was provided by Gattefosse (Cedex,
France) and has m.p. 50 C and HLB 13. All other materials
and reagents were of analytical grade of purity.
2.2. Methods
2.2.1. Preparation of physical mixture
Gelucire is a waxy pellet, so it is crushed to ﬁne particles ﬁrstly
to prepare the physical mixture. Physical mixtures (PMs) of
IND with PEG4000 or Gelucire 50/13, at 1:1, 1:2 and 1:4
weight ratio of IND:drug, were prepared by blending them
by trituration for 10 min followed by sieving (500 lm).
2.2.2. Preparation of solid dispersion
Solid dispersions (SDs) at various weight ratios were prepared
by melting method. IND was added to the molten base com-
prising PEG4000 or Gelucire. The blend was heated 10 C
above the melting point of each carrier for 5 min with contin-
uous stirring. The systems were placed in a freezer at 20 C
for 24 h. The mass was crushed, ground gently with a mortar
and pestle and passed through 500-lm sieve. The samples were
kept in a desiccator until the next experiments
2.2.3. Scanning electron microscopy (SEM)
The samples were coated with a thin gold layer by sputter coat-
er unit (SPI, sputter, USA). Then, SEM photographs were ta-
ken by a scanning electron microscope (Joel JSM 5400LV
SEM, Japan) operated at an acceleration voltage of 15 kV.
2.2.4. Differential scanning calorimetry (DSC)
The powdered sample (3–5 mg) was hermetically sealed in
aluminum pans and heated at a constant rate of 10 C/min,
over a temperature range of 25–200 C. Thermograms of the
samples were obtained using differential scanning calorimetry
(DSC-60, Shimadzu, Japan). Thermal analysis data were
recorded using a TA 50I PC system with Shimadzu software
programs. Indium standard was used to calibrate the DSC
temperature and enthalpy scale. N2 as purging gas at rate of
30 ml/min.
2.2.5. X-ray powder diffraction (XRD)
Samples were irradiated with monochromatized Cu Ka radia-
tion (1.542 A˚) and analyzed between 2 and 40 (2h) employing
a Philips FW 1700 X-ray diffractometer (Philips, Netherlands).
The voltage and current used were 40 kV and 30 mA, respec-
tively. The chart speed was 10 mm/s.
2.2.6. Solubility determination
An excess amount of the sample was placed in contact with
phosphate buffer pH 7.4. The samples were shaken for 48 h
at 37 C in a horizontal shaker. The supernatant was ﬁltered
through a Millipore ﬁlter (pore size 0.45 lm). 0.5 ml of the ﬁl-
Figure 2 SEM micrographs for indomethacin–Geluire systems:
indomethacin (IND), Geluire (Gelu. 50/13), physical mixture
(PM) and solid dispersion (SD) at 1:4 ratio.
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cally at 320 nm. All experiments were conducted in duplicate.
2.2.7. Release rate studies
USP type II (paddle) method using Electrolab dissolution tes-
ter (TDT06 N, India) was adopted. Amount of samples equiv-
alent to 50 mg of drug were dispersed into the dissolution
vessel containing 900 ml of 0.1 N HCl or phosphate buffer
(pH 7.4). The dissolution media were maintained at
37 C± 0.5 C and stirred at 50 rpm. Samples were collected
periodically and replaced with a fresh dissolution medium.
After ﬁltration through microﬁlter (0.45 lm), concentration
of IND was determined spectrophotometrically (Jenway 6305
spectrophotometer, UK) at 320 nm. All experiments were car-
ried out in duplicate.
3. Results and discussion
3.1. Scanning electron microscopy (SEM)
Figs. 1 and 2 display SEM photographs for IND, PEG4000,
Gelu. 50/13, their corresponding PMs and SDs. The drug
crystals seemed to be irregular in shape and size. IND crystals
were much smaller than PEG or Gelucire particles. The phys-
ical mixture of the drug and carrier showed the presence of
drug in the crystalline form. It was easy to recognize the poly-
mer particles from that of drug despite the reduction in size of
particles of polymers during mixing and its presence in high
amount (1:4 ratio). In case of SDs, it was difﬁcult to distin-
guish the presence of IND crystals. IND crystals appeared to
be incorporated into the particles of the polymers. The solid
dispersion looked like a matrix particle. The results could be
attributed to dispersion of the drug in the molten mass of
the polymer.Figure 1 SEM micrographs for indomethacin–PEG systems:
indomethacin (IND), polyethyleneglycol 4000 (PEG4000), phys-
ical mixture (PM) and solid dispersion (SD) at 1:4 ratio.3.2. X-ray powder diffraction (XRD)
XRD patterns for different samples are displayed in Figs. 3
and 4 for IND–PEG4000 and IND–Gelu. 50/13 systems,
respectively. The diffraction spectrum of pure IND showed
that the drug is highly crystalline powder and possesses sharp
peaks at 2h equal to 11.6, 16.4, 19.6, 21.7, 26.89 and 29.3.
This corresponds to the c-crystalline form polymorph of indo-
methacin (Pan et al., 2006). Characteristic peaks of PEG4000
(Fig. 3) appeared at 2h equal to 13.68, 19.24, 23.32 and
27.37. Gelucire showed two prominent peaks with the highest
intensity at 2h of 19.13 and 23.25 (Fig. 4).
All the principles peaks from PEG4000 (Fig. 3) and Geluc-
ire 50/13 (Fig. 4) were present in their PMs but with lower
intensity. In the case of the PMs, diffractograms were simply
the sum of those of pure components and no interaction could
be detected between them particularly at lower ratios (1:1 and
1:2). In case of PM of IND–PEG4000 system at 1:4 ratio
(Fig. 3), there was a decrease in the intensity of IND but the
major peaks remained at the same positions. The intensity of
peaks reﬂected their mutual concentration. The decrease in
the intensity of the diffractogram in case of the SD appeared
at 1:2 ratio and the peaks of IND disappeared completely at
1:4 ratio. It could be attributed to the destruction of its crystal
lattice, because of melting of drug into carrier. The peaks asso-
ciated to the carriers are not shifted with respect to the physical
mixture. This suggested the formation of an insertion-type so-
lid where drug molecules found place inside the structure of the
carrier without or with a limited deformation of the original
crystal lattice. This is common in mixtures of polymeric
carriers with small amounts of low molecular weight drugs
(Kreuter, 1999). In case of IND–Gelu. 50/13 (Fig. 4), diffrac-
tograms of physical mixtures are simply the sum of those of
pure components in all cases while the intensity of the peaks
of IND diminished with the increase in polymer ratio in case
of SDs. Contrary to SD of PEG, the IND peaks remained
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Figure 4 XRD diffractograms of for: (IND) indomethacin;
(Gelu.) Gelucire 50/13, and their different systems prepared at
different ratios; (PM) physical mixture; (SD) solid dispersion.
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Figure 3 XRD diffractograms for: (IND) indomethacin; (PEG)
polyethylene glycol 4000, and their different systems prepared at
different ratios; (PM) physical mixture; (SD) solid dispersion.
220 M. El-Badry et al.viewed in higher ratio of polymer (1:4). From these results, it
emerged that the amount of Gelu. is not sufﬁcient to dissolve
the IND completely so oversaturation occurred and pure drug
crystals kept its structure inside the solid dispersion and ap-
peared in the diffractogram (Fig. 4). Much decreased crystal-
linity of IND was suggested in the SDs of IND–Gelu., at 1:4
ratio, than the PM of same ratio (Fig. 4). The results indicated
that both polymers affected the crystallinity of IND by differ-
ent degrees. The change in crystallinity was dependent on the
amount of polymer and solubility of drug in the polymer. At
1:4 ratio, the crystallinity of IND much decreased in case of
Gelu., while it converted to amorphous state in case of
PEG4000. No new peaks could be observed suggesting the ab-
sence of the chemical interaction between the drug and the car-
rier (Ahuja et al., 2007).
3.3. Differential scanning calorimetry (DSC)
Fig. 5 depicted thermograms of IND, PEG4000 their PMs and
SDs. IND displayed endothermic peak at 161.26 C corre-
sponding to its melting point. PEG showed endothermic peak
at 61.8 C due to its melting point. Thermal traces for PM or
SD at 1:1 ratios showed a very weak broad peak shifted to low-
er melting point. The peak appeared at 136.1 C with heat offusion about 5.2 J/g for PM and appeared at 115.52 C with
heat of fusion 7.2 J/g for SD (Table 1). At higher ratios (1:2
and 1:4), thermal proﬁles of both PMs and SDs exhibited a sin-
gle endothermic peak corresponding to the fusion of the car-
rier. No peak was present representing the melting of the
drug. The results were consisted with the previous data of
XRD patterns (Fig. 3). In other study (Ford and Rubinstein,
1978) the indomethacin–PEG6000 produced only one-peak
thermogram up to 40% w/w composition, while peaks related
to the fusion of both polymorphs I and II appeared at 80% w/w
indomethacin composition. Fini et al. (2005) reported that
during the scanning of the temperature, the solid drug (diclofe-
nac) dissolved into the molten PEG6000 starting from 60 C
and is no more present in its undissolved form inside the sys-
tem. The results suggested that IND dissolved completely into
polymer.
Fig. 6 demonstrates thermograms of IND, Gelucire 50/13,
their PMs and SDs. The endotherm of Gelu. displayed broad
peak appeared at 46.56 C corresponding to its melting point
with heat of fusion 160 J/g (Khan and Craig, 2003). This
could be attributed to its composition, whereas, it is composed
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Figure 5 DSC thermograms for: (IND) indomethacin; (PEG)
polyethylene glycol 4000, and their different systems prepared at
different ratios; (PM) physical mixture; (SD) solid dispersion.
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Figure 6 DSC thermograms for: (IND) indomethacin; (Gelu.)
Gelucire 50/13, and their different systems prepared at different
ratios; (PM) physical mixture; (SD) solid dispersion.
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(Tantishaiyakul et al., 1999). The thermal behavior of both
PMs and SDs of the drug was different. In case of PM (1:1),
the peak of IND was weekend, broadened and appeared at
150.72 C with heat of fusion – 50.4 while it became trace
and shifted to 135.85 C with heat of fusion – 15.6 J/g at 1:2
ratio and disappeared completely in case of 1:4 ratio. At 1:1 ra-
tio of SD, the peak of IND appeared at 135.83 C with heat of
fusion – 22.8 J/g and disappeared completely at 1:2 and 1:4 ra-
tios. The differences in the thermal behavior of IND in form of
PMs and SDs suggested the drug crystallinity decreased whenTable 1 Solubility and thermal parameters of indomethacin (IND)
System type Ratio IND–PEG4000
Thermal parameters
Onset
temperature (C)
Peak
temperature (C)
Heat of
fusion (J/g)
Solu
(mg
IND 1:0 151.24 161.26 50.7 0.22
PEG 0:1 56.43 61.82 160
Gelu. 0:1
PM 1:1 128.92 136.61 5.2 0.29
1:2 – – – 0.36
1:4 – – – 0.40
SD 1:1 126.82 115.52 7.2 0.61
1:2 – – – 0.76
1:4 – – – 0.97
a Solubility was determined in phosphate buffer (pH 7.4).prepared as SD and that decrease was dependent on the ratio
of the polymer. The low amount of crystals dissolved in the
molten mass of Gelu. during DSC scanning and the peak of
drug melting disappeared. In case of PM (1:1 and 1:2), the
amount of molten polymer was not sufﬁcient to dissolve the
crystals of IND due to its presence in high amount. Increasing
the amount of polymer (1:4 ratio), the molten mass became
sufﬁcient to dissolve the drug and consequently disappeared
in the scan of PM. The difference between the effect of PEG
and Gelu. on IND’s crystallinity, probably, due to the lower
crystalline nature of Gelucire with respect to PEG (Fini
et al., 2005). The results from DSC and XRD indicated a de-
crease in crystallinity of IND in presence of higher amount
of Gelucire.alone and IND–polymer systems.
IND–Gelu. 50/13
Thermal parameters
bilitya
/ml)
Onset
temperature (C)
Peak
temperature (C)
Heat of
fusion (J/g)
Solubility
(mg/ml)
3
37.05 46.56 150 –
7 137.19 150.72 50.4 0.280
7 123.01 135.85 15.6 0.317
1 – – – 0.354
1 119.3 135.83 22.8 0.528
4 – – – 0.617
4 – – – 0.739
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Figure 8 Dissolution proﬁles for IND–Gelucire 50/13 systems in
0.1 N HCl prepared at different ratios of IND:Gelu. (IND)
indomethacin alone; (PM) physical mixture; (SD) solid dispersion.
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222 M. El-Badry et al.All PMs and SDs (Figs. 5 and 6) exhibited endothermic
peaks due to the fusion of PEG4000 and Gelucire 50/13
around 62 C and 45 C, respectively. This revealed the exis-
tence of both polymers in the crystalline state that was consis-
tent with the appearance of diffraction peaks in the
corresponding XRD pattern.
3.4. Solubility determination
The aqueous solubility of a drug is a prime determinant of its
dissolution rate and compounds with aqueous solubility less
than 0.1 mg/ml often present dissolution limitation to absorp-
tion. IND (pKa 4.5) can be considered practically insoluble
drug in simulated gastric ﬂuid (pH 1.2) and slightly soluble
in simulated intestinal ﬂuid (pH 7.4) (Nokhodchi et al.,
2005). The solubility of IND in phosphate buffer pH 7.4 was
markedly increased in presence of PEG or Gelucire (Table
1). For instance, the solubility of IND at 37 C increased 4-
folds or 3.5-fold when IND formulated as SD at 1:4 ratio in
PEG4000 or Gelucire 50/13, respectively. In general, the in-
crease in solubility of IND was greater in SDs than in PMs
(Table 1). It was shown that PEG4000 had solubilizing effect
higher than Gelucire 50/13. The results conﬁrmed that the ex-
tent of disruption of crystallinity of IND by PEG4000 was
higher than that by Gelu.
3.5. Release rate studies
Drug release studies were carried out in 0.1 N HCl (Figs. 7 and
8) and phosphate buffer pH 7.4 (Figs. 9 and 10). Generally, the
release of IND in phosphate buffer pH 7.4 was higher than
that in 0.1 N HCl. The result was explained on the basis of
the limited solubility of IND in acidic medium (Nokhodchi
et al., 2005). Blending of IND with PEG4000 or Gelucire in
form of PMs or SDs could enhance the release of IND. The
faster dissolution rate of PMs compared to pure drug was ob-
served for both of polymers and could be attributed to the0
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Figure 7 Dissolution proﬁles for IND–PEG4000 systems in
0.1 N HCl prepared at different ratios of IND:PEG4000. (IND)
indomethacin alone; (PM) physical mixture; (SD) solid dispersion.
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Figure 9 Dissolution proﬁles for IND–PEG4000 systems in
phosphate buffer pH 7.4 prepared at different ratios of
IND:PEG4000. (IND) indomethacin alone; (PM) physical mix-
ture; (SD) solid dispersion.improvement of wettability of IND particles due to the pres-
ence of highly hydrophilic polymers (Ahuja et al., 2007). Dis-
solution rates for SDs were greater than those for PMs and
IND alone. The enhanced dissolution rates of SDs may be
due to many factors such as decreased particle size of drug,
speciﬁc form of drug in these SDs, in addition to the increase
in drug wettability and preventing of drug aggregation by each
polymer (Tantishaiyakul et al., 1999). Furthermore, both PEG
and Gelucire affected the crystallinity of the drug could be
considered as an important factor in enhancement the dissolu-
tion rate. It is known that amorphous drug represents the most
ideal case for fast dissolution (Hancock and Zograﬁ, 1997).
The percent of drug dissolved after 90 min (DP) and rela-
tive dissolution rate (RDR) after 30 min of IND, physical mix-
Table 2 The percent of drug dissolved after 90 min (DP) and relative dissolution rate (RDR) after 30 min of indomethacin, physical
mixture and its solid dispersions in PEG4000 or Gelucire 50/13 prepared at different drug:polymer ratios.
Dissolution medium Polymer type Ratio PM SD
DP90 RDR30 DP90 RDR30
pH 1.2 Drug 14.5 1.0 14.5 1.0
PEG4000 1:1 15.2 1.58 19.9 1.63
1:2 31.1 1.73 30.1 1.92
1:4 35.2 1.92 39.8 2.05
Gelucire 1:1 14.5 1.09 20.2 1.57
1:2 14.9 1.12 21.4 1.61
1:4 15.2 1.22 30.0 1.92
pH 7.4 Drug 72.5 1.0 72.5 1.0
PEG4000 1:1 74.2 1.03 98.2 2.25
1:2 76.2 1.05 98.6 2.25
1:4 87.1 1.1 98.9 2.26
Gelucire 1:1 80.1 1.46 82.5 1.53
1:2 90.2 1.69 91.4 1.90
1:4 98.1 1.94 99.2 2.05
DP: percent of drug dissolved after 90 min.
RDR: relative dissolution rate (ratio between the IND dissolved from PM, SD, and that dissolved from drug alone at 30 min).
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Figure 10 Dissolution proﬁles for IND–Gelucire 50/13 systems
in phosphate buffer pH 7.4 prepared at different ratios of
IND:Gelu. (IND) indomethacin alone; (PM) physical mixture;
(SD) solid dispersion.
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prepared at different drug:polymer ratios were illustrated in
Table 2. It is shown that, the maximum percent amount of
drug dissolved at pH 1.2 was 39.8% and the (RDR30) values
were in the range 1.09–1.92 for PM and 1.61–2.05 for SD of
the used polymers. On the other hand, at the pH 7.4 the per-
cent of drug dissolved after time period was different accord-
ing to the polymer used and the (RDR30) values were in the
range 1.03–1.94 for PM and 1.53–2.27 for SD.
4. Conclusions
The study has demonstrated that dispersions of IND into
water-soluble carriers like PEG4000 or Gelucire 50/13 changedthe crystallinity of IND according to type and amount of the
polymer. The formation of IND–PEG solid dispersion de-
stroyed almost completely the crystallinity of the drug and rep-
resents a suitable modiﬁcation for improving its availability.
The higher ratio of Gelu. (1:4) tested in this study was not suf-
ﬁcient for conversion of IND to amorphous form. However, it
decreased the crystallinity of IND. Many factors contributed
to faster release rate such as decrease in particle size, decrease
in agglomeration of particles, increase wetability and decrease
in crystallinity of the drug.References
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